13 recruiting, 9 completed, 8 active not recruiting, 3 not yet recruiting. 36 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 36 | Recruiting 13, Completed 9, Active not recruiting 8, Not yet recruiting 3, Unknown 2, Terminated 1 |
Follow Akeso: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma Cadonilimab, CAPOX regimen, Nivolumab - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 900 | 2026-09-24 | 2026-09-29 |
| Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer Cadonilimab (AK104), Oxaliplatin, Capecitabine - Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | Phase 3 | Recruiting | Akeso | 386 | 2026-04-15 | 2026-04-22 |
| A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma AK104(SC), AK104(IV), Capecitabine - Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 3 | Not yet recruiting | Akeso | 422 | 2026-03-31 | 2026-03-04 |
| A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma Cadonilimab, SOX chemotherapy, Placebo - Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 3 | Recruiting | Akeso | 760 | 2025-08-14 | 2026-02-11 |
| Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer Ivonescimab, docetaxel, Placebo, docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Akeso | 536 | 2025-07-08 | 2026-04-09 |
| A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy AK112, Placebo - Small Cell Lung Cancer | Phase 3 | Recruiting | Akeso | 560 | 2025-06-13 | 2026-03-05 |
| A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 3 | Recruiting | Akeso | 999 | 2025-06-11 | 2026-03-04 |
| AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer AK112, Oxaliplatin, Irinotecan - Colorectal Adenocarcinoma | Phase 3 | Recruiting | Akeso | 560 | 2025-05-27 | 2026-03-04 |
| AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer AK112, Nab-paclitaxel, Placebo - Triple-Negative Breast Cancer (TNBC) | Phase 3 | Recruiting | Akeso | 416 | 2025-02-07 | 2026-03-16 |
| A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis Placebo, placebo - Atopic Dermatitis | Phase 3 | Not yet recruiting | Akeso | 198 | 2025-01-23 | 2025-01-10 |
| A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC Cadonilimab (AK104), Sugemalimab - NSCLC (Non-small Cell Lung Cancer) | Phase 3 | Recruiting | Akeso | 560 | 2024-11-12 | 2025-03-12 |
| A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) AK117 in combination with AK112, Placebo in combination with Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | Akeso | 510 | 2024-10-30 | 2024-11-14 |
| AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer AK112, Gemcitabine, Cisplatin, Durvalumab, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 3 | Active not recruiting | Akeso | 682 | 2024-10-20 | 2026-01-21 |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma AK104, Lenvatinib, TACE - Hepatocellular Carcinoma | Phase 3 | Recruiting | Akeso | 469 | 2024-08-02 | 2025-03-12 |
| A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma cadonilimab, pulocimab, paclitaxel - Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 506 | 2024-06-19 | 2024-06-24 |
| A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis AK120 - Atopic Dermatitis | Phase 3 | Unknown | Akeso | 420 | 2024-04-30 | 2024-04-25 |
| A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis AK111, Placebo+AK111 - Ankylosing Spondylitis | Phase 3 | Completed | Akeso | 510 | 2023-11-22 | 2026-10-16 |
| A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer AK104, Tislelizumab, carboplatin - Locally Advanced or Metastatic NSCLC | Phase 3 | Not yet recruiting | Akeso | 642 | 2023-11-14 | 2023-08-14 |
| AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel - Advanced Squamous Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | Akeso | 532 | 2023-08-17 | 2025-05-02 |
| Phase III Study of AK112 for NSCLC Patients AK112 Injection, Placebo Injection - Non-Squamous Non-small Cell Lung Cancer | Phase 3 | Active not recruiting | Summit Therapeutics | 420 | 2023-05-04 | 2026-07-28 |
Showing 20 of 36. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Hyperlipidemias (3) · Carcinoma, Hepatocellular (2) · Dermatitis, Atopic (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Nasopharyngeal Carcinoma (1) · Pancreatic Neoplasms (1) · Psoriasis (1) · Skin Diseases (1) · Small Cell Lung Carcinoma (1) · Spondylitis, Ankylosing (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Carboplatin (8) · Cisplatin (4) · Oxaliplatin (4) · Paclitaxel (4) · Pemetrexed (4) · Capecitabine (3) · Gemcitabine (3) · Bevacizumab (2) · Fluorouracil (2) · Leucovorin (2) · pembrolizumab (2) · penpulimab (2) · tislelizumab (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1)
China (34) · United States (3) · Canada (2) · Australia (1) · Brazil (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Spain (1) · United Kingdom (1)
Lin Shen, MD (3) · Baohui Han, MD (2) · Jiafu Ji, MD (2) · Shunchang Jiao, MD (2) · Caicun Zhou (1) · Chaosu Hu, MD (1) · Gaojun Teng, MD (1) · Guoliang Shao, MD (1) · Jia Fan, Ph.D. (1) · Jie Wang, M.D. (1) · Jihong Liu, Ph.D (1) · Jinming Yu, MD (1) · Li Zhang, MD (1) · Markus Mohler, MD (1) · Qingming Wang (1)
PMID 35833116, PMID 38309287, PMID 38820549, PMID 39426385, PMID 39843940, PMID 40057343, PMID 41457351, PMID 41946687, PMID 42218899, PMID 42233228, PMID 42307937, PMID 42636833